(Q34154647)

31 July 2017

0 references

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials (English)

1 reference

31 July 2017

0 references

0 references

1 reference

1

M D Ferrari

1 reference

31 July 2017

4

R B Lipton

1 reference

31 July 2017

2

P J Goadsby

1 reference

31 July 2017

K I Roon

3

1 reference

PubMed ID

12383060

31 July 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

31 July 2017

1 reference

31 July 2017

22

1 reference

31 July 2017

633-658

1 reference

31 July 2017

8

1 reference

Migraine--current understanding and treatment

31 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Ergotamine in the acute treatment of migraine: a review and European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

The pharmacology of headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

21 January 2018

Serotonin and migraine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

SUMATRIPTAN: a receptor-targeted treatment for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

The mode of action of sumatriptan is vascular? A debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Tolerability of sumatriptan: clinical trials and post-marketing experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Methodology of clinical trials of sumatriptan in migraine and cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Pathophysiology and management of the serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Serotonin syndrome complicating migraine pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Determinants of patient satisfaction with migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Monitoring of acute migraine attacks: placebo response and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Sumatriptan and daily headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Using numerical results from systematic reviews in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Within-patient consistency of response of rizatriptan for treating migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Characteristics and determinants of sumatriptan-associated chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Oral sumatriptan compared with placebo in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Sumatriptan in the Treatment of Acute Migraine With Aura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Zolmitriptan provides consistent migraine relief when used in the long-term

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

A long-term study to maximise migraine relief with zolmitriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

Oral sumatriptan in acute migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00404.X

10.1046/J.1468-2982.2002.00404.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12383060